Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) will be issuing its quarterly earnings data after the market closes on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.32) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.
Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.02. Adaptive Biotechnologies had a negative return on equity of 56.58% and a negative net margin of 123.24%. The company had revenue of $41.87 million for the quarter, compared to analyst estimates of $38.78 million. During the same quarter last year, the firm posted ($0.40) EPS. The firm’s revenue for the quarter was up 11.2% on a year-over-year basis. On average, analysts expect Adaptive Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Adaptive Biotechnologies Stock Up 3.6 %
Adaptive Biotechnologies stock opened at $4.60 on Wednesday. The company has a fifty day simple moving average of $3.64 and a 200-day simple moving average of $3.52. The firm has a market capitalization of $677.90 million, a price-to-earnings ratio of -3.09 and a beta of 1.35. Adaptive Biotechnologies has a 52-week low of $2.28 and a 52-week high of $8.51.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on Adaptive Biotechnologies
Adaptive Biotechnologies Company Profile
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Further Reading
- Five stocks we like better than Adaptive Biotechnologies
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- How to buy stock: A step-by-step guide for beginners
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Which Wall Street Analysts are the Most Accurate?
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.